Source: Access Newswire
Zomedica Corp. (NYSE American: ZOM), a Veterinary health company, announced that its common shares will be delisted from the NYSE American exchange due to low share price. The company will transition to the OTCQB Venture Market under the ticker “ZOMDF”, effective March 5, 2025.
CEO Larry Heaton expressed disappointment but emphasized that the company’s assets and growth opportunities remain unchanged. Zomedica will continue to engage investors, file SEC reports, and maintain regulatory compliance. The company specializes in diagnostic and therapeutic solutions for equine and companion animals, including PulseVet® shock wave therapy, TRUFORMA® diagnostics, and VetGuardian® no-touch monitoring. With a U.S. market exceeding $2 billion, Zomedica aims to expand internationally and enhance Veterinary care.
Despite the delisting, investors can still access trading data and company updates through OTC Markets and Zomedica’s investor relations page. The company remains committed to innovation and Veterinary industry advancements.